Lechenie i profilaktika zheludochno-kishechnykh krovotecheniy u bol'nykh, poluchayushchikh antiagregantnuyu/antikoagulyantnuyu terapiyu


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to the evaluation of the efficacy, tolerability and safety of the drug Controloc for the treatment of bleeding associated with erosive and ulcerative lesions of the stomach and duodenum. The drug was administered in 20 patients receiving antiplatelet/ anticoagulation therapy at a dose of 80 mg as intravenous bolus followed by infusion of 8 mg/hr continuously for 72 hours. Thereafter, Controloc was administered at a dose of 40 mg 2 times a day orally for a month. During the study period, no other proton pump inhibitors were administered. The analysis of the dynamics of endoscopic, clinical and laboratory parameters was used for the objective evaluation of the effectiveness. After 1 month, 19 (95 %) patients had a full arrest of bleeding; repair of erosive and ulcerative lesions occurred at the 4th week in the absence of complications/adverse reactions, which allowed to estimate the effectiveness as «excellent». 1 (5 %) patient had partial healing of erosive and ulcerative lesions; the efficiency in this case was rated as «good». The study indicates the efficacy and safety of treatment and prevention of gastrointestinal bleeding using Controloc in patients with pathology of the cardiovascular system, receiving antiplatelet/anticoagulant therapy.

Full Text

Restricted Access

References

  1. Минушкин О.Н., Л.В.Масловский, Шулешова А.Г., Голикова З.Н. Профилактика желудочно-кишечных кровотечений у больных, получающих антикоагулянтную и/ или антиагрегантную терапию// Кремлевская медицина. Клинический вестник 2012. № 1. С.139-42.
  2. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010.
  3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/no-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007; 50(7):1-157.
  4. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
  5. American Diabetes Association: Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl. 1):S12-S54.
  6. Barkun A, Bardou M, Kuipers E, et al. International Consensus Upper Gastrointestinal Bleeding Conference Group. Ann. Intern Med 2010;152:101-13.
  7. Bassand JP, Hamm CW, Ardissino D, et al.; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007;28(13):1598-660.
  8. Dalton D, Grant-Casey J, Hearnshaw S, et al. The UK comparative audit of upper gastrointestinal bleeding and the use of blood. Oxford, 2007.
  9. Gilard M, Arnaud B, Comily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256-60.
  10. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-47.
  11. shizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl. 3):27-36.
  12. uurlink DN, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18.
  13. King III SB, Smith Jr. SC, Hirshfeld Jr JW, et al. 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117:261-95.
  14. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009;7:33-47.
  15. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:286-96.
  16. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009;374:989-97.
  17. Romagnuolo J, Barkun AN, Enns R, et al. Simple Clinical Predictors May Obviate Urgent Endoscopy in Selected Patients With Nonvariceal Upper Gastrointestinal Tract Bleeding ARCH INTERN MED 2007;167:265-70.
  18. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
  19. Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction. Lancet 2009;374:952-53.
  20. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45.
  21. Van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/ 1994 and 2000. Am J Gastroenterol 2003;98: 1494-99.
  22. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can JCardiol 2010;26:54-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies